These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33768568)

  • 1. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression.
    Di-Luoffo M; Pirenne S; Saandi T; Loriot A; Gérard C; Dauguet N; Manzano-Núñez F; Alves Souza Carvalhais N; Lamoline F; Cordi S; Konobrocka K; De Greef V; Komuta M; Halder G; Jacquemin P; Lemaigre FP
    Hepatology; 2021 Sep; 74(3):1445-1460. PubMed ID: 33768568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
    Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
    J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.
    Yang CY; Huang WJ; Tsai JH; Cheng A; Chen CC; Hsu HP; Jeng YM
    Mod Pathol; 2019 Nov; 32(11):1637-1645. PubMed ID: 31231124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
    J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Hill MA; Alexander WB; Guo B; Kato Y; Patra K; O'Dell MR; McCall MN; Whitney-Miller CL; Bardeesy N; Hezel AF
    Cancer Res; 2018 Aug; 78(16):4445-4451. PubMed ID: 29871934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP-1 selectively impairs
    Keggenhoff FL; Castven D; Becker D; Stojkovic S; Castven J; Zimpel C; Straub BK; Gerber T; Langer H; Hähnel P; Kindler T; Fahrer J; O'Rourke CJ; Ehmer U; Saborowski A; Ma L; Wang XW; Gaiser T; Matter MS; Sina C; Derer S; Lee JS; Roessler S; Kaina B; Andersen JB; Galle PR; Marquardt JU
    Gut; 2024 Sep; 73(10):1712-1724. PubMed ID: 38857989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent Mutations in APC and CTNNB1 and Activated Wnt/β-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct: A Whole Exome Sequencing Study.
    Fujikura K; Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Am J Surg Pathol; 2018 Dec; 42(12):1674-1685. PubMed ID: 30212390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brahma-Related Gene 1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Zhou Y; Chen Y; Zhang X; Xu Q; Wu Z; Cao X; Shao M; Shu Y; Lv T; Lu C; Xie M; Wen T; Yang J; Shi Y; Bu H
    Hepatology; 2021 Aug; 74(2):797-815. PubMed ID: 33650193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of FGF10-ERK signal activation suppresses intraductal papillary neoplasm of the bile duct and its associated carcinomas.
    Tomita H; Tanaka K; Hirata A; Okada H; Imai H; Shirakami Y; Ohnishi K; Sugie S; Aoki H; Hatano Y; Noguchi K; Kanayama T; Niwa A; Suzui N; Miyazaki T; Tanaka T; Akiyama H; Shimizu M; Yoshida K; Hara A
    Cell Rep; 2021 Feb; 34(8):108772. PubMed ID: 33626352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice.
    Yang Y; Wang J; Wan J; Cheng Q; Cheng Z; Zhou X; Wang O; Shi K; Wang L; Wang B; Zhu X; Chen J; Feng D; Liu Y; Jahan-Mihan Y; Haddock AN; Edenfield BH; Peng G; Hohenstein JD; McCabe CE; O'Brien DR; Wang C; Ilyas SI; Jiang L; Torbenson MS; Wang H; Nakhleh RE; Shi X; Wang Y; Bi Y; Gores GJ; Patel T; Ji B
    J Hepatol; 2024 Jul; 81(1):120-134. PubMed ID: 38428643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
    Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
    Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.
    Cigliano A; Gigante I; Serra M; Vidili G; Simile MM; Steinmann S; Urigo F; Cossu E; Pes GM; Dore MP; Ribback S; Milia EP; Pizzuto E; Mancarella S; Che L; Pascale RM; Giannelli G; Evert M; Chen X; Calvisi DF
    J Exp Clin Cancer Res; 2024 Sep; 43(1):253. PubMed ID: 39243039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes.
    Aoki Y; Mizuma M; Hata T; Aoki T; Omori Y; Ono Y; Mizukami Y; Unno M; Furukawa T
    J Pathol; 2020 May; 251(1):38-48. PubMed ID: 32100878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
    Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
    Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
    Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
    Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
    Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
    Xu L; Zhang Y; Lin Z; Deng X; Ren X; Huang M; Li S; Zhou Q; Fang F; Yang Q; Zheng G; Chen Z; Wu Z; Sun X; Lin J; Shen J; Guo J; Li X; Xue T; Tan J; Lin X; Tan L; Peng H; Shen S; Peng S; Li S; Liang L; Cleary JM; Lai J; Xie Y; Kuang M
    J Hepatol; 2024 Aug; 81(2):265-277. PubMed ID: 38508240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.